Data from Murine Cell Lines Derived from <i>Pten</i> Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

Jing Jiao,Shunyou Wang,Rong Qiao,Igor Vivanco,Philip A. Watson,Charles L. Sawyers,Hong Wu
DOI: https://doi.org/10.1158/0008-5472.c.6495606
2023-01-01
Abstract:<div>Abstract<p><i>PTEN</i> mutations are among the most frequent genetic alterations found in human prostate cancers. Our previous works suggest that although precancerous lesions were found in <i>Pten</i> heterozygous mice, cancer progression and metastasis only happened when both alleles of <i>Pten</i> were deleted. To understand the molecular mechanisms underlying the role of PTEN in prostate cancer control, we generated two pairs of isogenic, androgen receptor (AR)–positive prostate epithelial lines from intact conditional <i>Pten</i> knock-out mice that are either heterozygous (PTEN-P2 and -P8) or homozygous (PTEN-CaP2 and PTEN-CaP8) for <i>Pten</i> deletion. Further characterization of these cells showed that loss of the second allele of <i>Pten</i> leads to increased anchorage-independent growth <i>in vitro</i> and tumorigenesis <i>in vivo</i> without obvious structural or numerical chromosome changes based on SKY karyotyping analysis. Despite no prior exposure to hormone ablation therapy, <i>Pten</i> null cells are tumorigenic in both male and female severe combined immunodeficiency mice. Furthermore, knocking down PTEN can convert the androgen-dependent Myc-CaP cell into androgen independence, suggesting that PTEN intrinsically controls androgen responsiveness, a critical step in the development of hormone refractory prostate cancer. Importantly, knocking down AR by shRNA in <i>Pten</i> null cells reverses androgen-independent growth <i>in vitro</i> and partially inhibited tumorigenesis <i>in vivo</i>, indicating that PTEN-controlled prostate tumorigenesis is AR dependent. These cell lines will serve as useful tools for understanding signaling pathways controlled by PTEN and elucidating the molecular mechanisms involved in hormone refractory prostate cancer formation. [Cancer Res 2007;67(13):6083–91]</p></div>
What problem does this paper attempt to address?